Candel Therapeutics to Participate in Upcoming Investor Conferences in September

On August 28, 2025 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in upcoming investor conferences with associated one-on-one investor meetings (Press release, Candel Therapeutics, AUG 28, 2025, View Source [SID1234655560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2025 Biopharma Back to School Conference (Boston, MA)
Date/Time: Wednesday, September 3, 2025, at 9:00 AM ET
Webcast Link: Citi / Candel Fireside Chat

Cantor Global Healthcare Conference (New York, NY)
Date/Time: Thursday, September 4, 2025, at 8:00 AM ET
Webcast Link: Cantor / Candel Fireside Chat

H.C. Wainwright 27th Annual Global Investment Conference (New York, NY)
Date/Time: Friday, September 5, 2025, at 7:00 AM ET
Webcast Link: H.C. Wainwright / Candel Presentation

Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.

Merus to Present at the 2025 Wells Fargo Healthcare Conference

On August 28, 2025 Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics, Triclonics and ADClonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET (Press release, Merus, AUG 28, 2025, View Source [SID1234655559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

On August 28, 2025 Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) reported that management will participate in fireside chats at the following investor conferences in September (Press release, Kiniksa Pharmaceuticals, AUG 28, 2025, View Source [SID1234655558]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time
2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time

A live webcast of Kiniksa’s presentations will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the events will also be available on Kiniksa’s website within approximately 48 hours after the event.

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

On August 28, 2025 TG Therapeutics, Inc. (NASDAQ: TGTX) reported that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, reported it will participate in the Cantor Global Healthcare Conference, being held in New York, NY on September 3 – 5, 2025 (Press release, TG Therapeutics, AUG 28, 2025, View Source [SID1234655557]). The fireside chat is scheduled to take place on Wednesday, September 3, 2025, at 10:20am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

On August 28, 2025 TOLREMO therapeutics AG (TOLREMO), reported that their lead candidate, TT125-802, received two Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) (Press release, TOLREMO, AUG 28, 2025, View Source [SID1234655556]). One Fast Track designation was granted for the treatment of patients with locally advanced or metastatic NSCLC with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation, with disease progression on at least one line of prior therapy including an EGFR inhibitor. The second Fast Track designation was granted for the treatment of patients with locally advanced or metastatic kirstin rat sarcoma viral oncogene homolog (KRAS)-G12C mutated NSCLC, with disease progression on at least one line of prior therapy including a KRAS G12C inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TT125-802 is an orally available small-molecule inhibitor of CBP/p300, a fundamental driver of cancer cell survival and treatment resistance that functions in parallel to primary oncogenic pathways. Encouraging initial efficacy and safety data from the first-in-human Phase 1 clinical trial, presented at ASCO (Free ASCO Whitepaper) 2025, demonstrated impressive clinical monotherapy activity in solid tumors without causing thrombocytopenia.

"NSCLC is a major cause of cancer-related death. While oncogene-targeting drugs such as EGFR and KRAS inhibitors improve overall survival, a significant number of patients eventually experience disease progression, representing a high unmet medical need," said Stefanie Flückiger-Mangual, PhD, Chief Executive Officer at TOLREMO. "TT125-802 has the potential to address this challenge by blocking transcriptional pathways that drive tumor growth and treatment evasion in parallel to the driving oncogene. This is supported by our clinical data to date, demonstrating deep and durable responses to TT125-802 as a single agent in patients with drug- resistant KRAS-G12C- or EGFR-mutant NSCLC. The Fast Track designations in these indications provide us with an accelerated path on our mission to deliver our differentiated treatment approach to patients who urgently need it."

"TT125-802’s highly selective mechanism of action and favorable safety profile without thrombocytopenia differentiate it from other agents in the class," added Alan Sandler, MD, Scientific Advisory Board member at TOLREMO. "The two Fast Track designations highlight TT125-802’s broad potential to provide a new approach for tackling drug resistance and tumor survival in solid tumors, including EGFR- and KRAS-G12C mutant NSCLC. We are looking forward to working closely with the FDA to advance the clinical evaluation of TT125-802 as an innovative backbone therapy."

FDA Fast Track status is designed to facilitate the development and expedite the review of new therapies that are intended to treat serious conditions with unmet medical need. Programs granted Fast Track designation have access to more frequent interactions with the FDA during clinical development and may be eligible for accelerated approval and/or priority review if certain criteria are met.

TOLREMO is assessing TT125-802 in a first-in-human, multicenter Phase 1 trial (NCT06403436) to evaluate the safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors. The Fast Track designations will support the company’s clinical development strategy to advance TT125-802 in combination with an oncogene-targeting drug in KRAS- and EGFR-mutated NSCLC.